Brief: Seastar Medical Announces Activation Of First Clinical Site In Pivotal Trial With Selective Cytopheretic Device In Critically Ill Adults With Acute Kidney Injury
19/04/2023 13:12
April 19 (Reuters) - SeaStar Medical Holding Corp
ICU.O :
* SEASTAR MEDICAL ANNOUNCES ACTIVATION OF FIRST CLINICAL
SITE IN
PIVOTAL TRIAL WITH SELECTIVE CYTOPHERETIC DEVICE IN CRITICALLY
ILL ADULTS WITH ACUTE KIDNEY INJURY
Source text for Eikon: ID:nGNX6J2ZQl
Further company coverage: ICU.O
Recent news on SeaStar Medical Holding
See all newsBrief: FDA Grants Seastar Medical Breakthrough Device Designation For Its Scd Therapy For The Treatment Of Hyperinflammation In Adult Patients With Sepsis Or A Septic Condition
SeaStar Medical Holding Corp reports results for the quarter ended June 30 - Earnings Summary
SeaStar Medical Q2 revenue jumps 82% on QUELIMMUNE demand
Brief: SeaStar Medical Q2 EPS USD -0.91
SeaStar Medical Holding Corp expected to post a loss of 97 cents a share - Earnings Preview